Hematological involvement in sarcoidosis: from cytopenias to lymphoma
We present an updated overview of the hematological involvementassociated with sarcoidosis, including a management approach forcytopenias and revisiting the association with hematologicalmalignancies.AREAS COVERED: Theetiology of cytopenias in sarcoidosis can be attributed to two majoretiopathogenic mechanisms: infiltration of hematopoietic organs suchas the spleen and bone marrow, and autoimmune-mediated cytopenias.With respect to the association with hematological malignancies, itrequires careful evaluation of patients from a chronologicalperspective. Patients must be classified into one of three pathogenicscenarios, inc...
Source: Clinical Lymphoma and Myeloma - October 25, 2023 Category: Cancer & Oncology Authors: Pilar Brito-Zer ón Elyse E Lower Manuel Ramos-Casals Robert P Baughman Source Type: research
Hematological involvement in sarcoidosis: from cytopenias to lymphoma
We present an updated overview of the hematological involvementassociated with sarcoidosis, including a management approach forcytopenias and revisiting the association with hematologicalmalignancies.AREAS COVERED: Theetiology of cytopenias in sarcoidosis can be attributed to two majoretiopathogenic mechanisms: infiltration of hematopoietic organs suchas the spleen and bone marrow, and autoimmune-mediated cytopenias.With respect to the association with hematological malignancies, itrequires careful evaluation of patients from a chronologicalperspective. Patients must be classified into one of three pathogenicscenarios, inc...
Source: Clinical Lymphoma and Myeloma - October 25, 2023 Category: Cancer & Oncology Authors: Pilar Brito-Zer ón Elyse E Lower Manuel Ramos-Casals Robert P Baughman Source Type: research
Hematological involvement in sarcoidosis: from cytopenias to lymphoma
We present an updated overview of the hematological involvementassociated with sarcoidosis, including a management approach forcytopenias and revisiting the association with hematologicalmalignancies.AREAS COVERED: Theetiology of cytopenias in sarcoidosis can be attributed to two majoretiopathogenic mechanisms: infiltration of hematopoietic organs suchas the spleen and bone marrow, and autoimmune-mediated cytopenias.With respect to the association with hematological malignancies, itrequires careful evaluation of patients from a chronologicalperspective. Patients must be classified into one of three pathogenicscenarios, inc...
Source: Clinical Lymphoma and Myeloma - October 25, 2023 Category: Cancer & Oncology Authors: Pilar Brito-Zer ón Elyse E Lower Manuel Ramos-Casals Robert P Baughman Source Type: research
Hottest topics in hematopoietic stem cell transplantation: a summary from the 8th International Transplant and Cellular Therapy Course
Clin Hematol Int. 2023 Oct 18;5(4):89034. doi: 10.46989/001c.89034. eCollection 2023.NO ABSTRACTPMID:37869470 | PMC:PMC10588818 | DOI:10.46989/001c.89034 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 23, 2023 Category: Cancer & Oncology Authors: Edwin U Su árez Source Type: research
Hottest topics in hematopoietic stem cell transplantation: a summary from the 8th International Transplant and Cellular Therapy Course
Clin Hematol Int. 2023 Oct 18;5(4):89034. doi: 10.46989/001c.89034. eCollection 2023.NO ABSTRACTPMID:37869470 | PMC:PMC10588818 | DOI:10.46989/001c.89034 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 23, 2023 Category: Cancer & Oncology Authors: Edwin U Su árez Source Type: research
Full-Dose Azacitidine in 5 Days Versus 7 Days With a Weekend Break in Myelodysplastic Syndromes: A Retrospective Cohort Study
CONCLUSIONS: In higher-risk MDS, full-dose azacitidine (7 × 75 mg/m2) can be administered both in 5 days and in 7 days with a weekend break with no significant difference in survival, infection or transfusional outcomes.PMID:37867093 | DOI:10.1016/j.clml.2023.09.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 22, 2023 Category: Cancer & Oncology Authors: Guilherme Sapinho L ídia Alves-Ribeiro Joana Infante Catarina Jacinto-Correia Sahir Kalim Jo ão F Lacerda Source Type: research
Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies
Clin Lymphoma Myeloma Leuk. 2023 Sep 19:S2152-2650(23)01549-5. doi: 10.1016/j.clml.2023.09.002. Online ahead of print.ABSTRACTThe emergence of immune checkpoint inhibitors (ICIs) has led to a dramatic paradigm shift within the landscape of cancer treatment, igniting significant interest in their potential application in treating hematologic malignancies. This comprehensive review critically has examined the existing body of literature to shed light on the evolving understanding of the efficacy and safety of ICIs, both as a single agent and in combination regimens in hematologic malignancies. Across distinct lymphoma subtyp...
Source: Clinical Lymphoma and Myeloma - October 20, 2023 Category: Cancer & Oncology Authors: Muhammed Talha Bilgihan Ayse Nur Eryigit Rafiye Ciftciler Source Type: research
Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies
Clin Lymphoma Myeloma Leuk. 2023 Sep 19:S2152-2650(23)01549-5. doi: 10.1016/j.clml.2023.09.002. Online ahead of print.ABSTRACTThe emergence of immune checkpoint inhibitors (ICIs) has led to a dramatic paradigm shift within the landscape of cancer treatment, igniting significant interest in their potential application in treating hematologic malignancies. This comprehensive review critically has examined the existing body of literature to shed light on the evolving understanding of the efficacy and safety of ICIs, both as a single agent and in combination regimens in hematologic malignancies. Across distinct lymphoma subtyp...
Source: Clinical Lymphoma and Myeloma - October 20, 2023 Category: Cancer & Oncology Authors: Muhammed Talha Bilgihan Ayse Nur Eryigit Rafiye Ciftciler Source Type: research
Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies
Clin Lymphoma Myeloma Leuk. 2023 Sep 19:S2152-2650(23)01549-5. doi: 10.1016/j.clml.2023.09.002. Online ahead of print.ABSTRACTThe emergence of immune checkpoint inhibitors (ICIs) has led to a dramatic paradigm shift within the landscape of cancer treatment, igniting significant interest in their potential application in treating hematologic malignancies. This comprehensive review critically has examined the existing body of literature to shed light on the evolving understanding of the efficacy and safety of ICIs, both as a single agent and in combination regimens in hematologic malignancies. Across distinct lymphoma subtyp...
Source: Clinical Lymphoma and Myeloma - October 20, 2023 Category: Cancer & Oncology Authors: Muhammed Talha Bilgihan Ayse Nur Eryigit Rafiye Ciftciler Source Type: research
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
CONCLUSION: Fedratinib appears to deliver spleen and symptom benefits in real-world patients with MF previously treated with ruxolitinib.PMID:37839939 | DOI:10.1016/j.clml.2023.09.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 15, 2023 Category: Cancer & Oncology Authors: John Mascarenhas Claire Harrison Tammy A Schuler Djibril Liassou Marn é Garretson Taavy A Miller Sankar Mahadevan Ali McBride Derek Tang Irene S DeGutis Pranav Abraham Jonathan Kish Bruce A Feinberg Aaron T Gerds Source Type: research
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
CONCLUSION: Fedratinib appears to deliver spleen and symptom benefits in real-world patients with MF previously treated with ruxolitinib.PMID:37839939 | DOI:10.1016/j.clml.2023.09.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 15, 2023 Category: Cancer & Oncology Authors: John Mascarenhas Claire Harrison Tammy A Schuler Djibril Liassou Marn é Garretson Taavy A Miller Sankar Mahadevan Ali McBride Derek Tang Irene S DeGutis Pranav Abraham Jonathan Kish Bruce A Feinberg Aaron T Gerds Source Type: research
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
CONCLUSION: Fedratinib appears to deliver spleen and symptom benefits in real-world patients with MF previously treated with ruxolitinib.PMID:37839939 | DOI:10.1016/j.clml.2023.09.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 15, 2023 Category: Cancer & Oncology Authors: John Mascarenhas Claire Harrison Tammy A Schuler Djibril Liassou Marn é Garretson Taavy A Miller Sankar Mahadevan Ali McBride Derek Tang Irene S DeGutis Pranav Abraham Jonathan Kish Bruce A Feinberg Aaron T Gerds Source Type: research
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
CONCLUSION: Fedratinib appears to deliver spleen and symptom benefits in real-world patients with MF previously treated with ruxolitinib.PMID:37839939 | DOI:10.1016/j.clml.2023.09.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 15, 2023 Category: Cancer & Oncology Authors: John Mascarenhas Claire Harrison Tammy A Schuler Djibril Liassou Marn é Garretson Taavy A Miller Sankar Mahadevan Ali McBride Derek Tang Irene S DeGutis Pranav Abraham Jonathan Kish Bruce A Feinberg Aaron T Gerds Source Type: research
Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations
J Clin Med. 2023 Oct 4;12(19):6356. doi: 10.3390/jcm12196356.ABSTRACTA Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary immunodeficiencies (SID) in the management of oncohematological patients. There was 100% agreement on the need to have available guidelines for the management of immunodeficiency in hematological patients; to perform a baseline immunological evaluation in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), lymphoma and hematopoietic stem cell transplantation (HSCT) recipients; ...
Source: Clinical Lymphoma and Myeloma - October 14, 2023 Category: Cancer & Oncology Authors: Concepci ón Boqué Silvia S ánchez-Ramón Ra úl Córdoba Carol Moreno Elena Cabezudo Source Type: research
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
CONCLUSION: DRd is associated with a significantly lower risk of disease progression or death compared to VRd as 1L treatment for TIE NDMM patients.PMID:37838502 | DOI:10.1016/j.clml.2023.09.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 14, 2023 Category: Cancer & Oncology Authors: Lucio Navarro Gordan Carlyn Rose Tan Robert Vescio Jing Christine Ye Carolina Schinke Rohan Medhekar Alex Z Fu Marie-H élène Lafeuille Philippe Thompson-Leduc Vipin Khare John Reitan Gary Milkovich Shuchita Kaila Faith Davies Saad Z Usmani Source Type: research
